blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP4332221

EP4332221 - THREOSE NUCLEIC ACID ANTISENSE OLIGONUCLEOTIDES AND METHODS THEREOF [Right-click to bookmark this link]
StatusThe application has been withdrawn
Status updated on  22.03.2024
Database last updated on 03.09.2024
FormerThe application has been published
Status updated on  02.02.2024
Most recent event   Tooltip22.03.2024Withdrawal of applicationpublished on 24.04.2024  [2024/17]
Applicant(s)For all designated states
Roche Innovation Center Copenhagen A/S
Fremtidsvej 3
2970 Hørsholm / DK
For all designated states
F. Hoffmann-La Roche AG
Grenzacherstrasse 124
4070 Basel / CH
[2024/10]
Representative(s)Rodriguez Novoa, Lorena
F. Hoffmann-La Roche AG Patent Department
Grenzacherstrasse 124
4070 Basel / CH
[2024/10]
Application number, filing date22192656.129.08.2022
[2024/10]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP4332221
Date:06.03.2024
Language:EN
[2024/10]
Search report(s)(Supplementary) European search report - dispatched on:EP22.05.2023
ClassificationIPC:C12N15/113, C12N15/11
[2024/10]
CPC:
C12N15/111 (EP); C12N15/113 (EP); C12N2310/11 (EP);
C12N2310/315 (EP); C12N2310/319 (EP); C12N2310/32 (EP);
C12N2310/3231 (EP); C12N2310/3341 (EP); C12N2310/341 (EP) (-)
C-Set:
C12N2310/321, C12N2310/3525 (EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2024/10]
Extension statesBANot yet paid
MENot yet paid
Validation statesKHNot yet paid
MANot yet paid
MDNot yet paid
TNNot yet paid
TitleGerman:THREOSE-NUKLEINSÄURE-ANTISENSE-OLIGONUKLEOTIDE UND VERFAHREN DAFÜR[2024/10]
English:THREOSE NUCLEIC ACID ANTISENSE OLIGONUCLEOTIDES AND METHODS THEREOF[2024/10]
French:OLIGONUCLÉOTIDES ANTISENS D'ACIDE NUCLÉIQUE À THRÉOSE ET PROCÉDÉS ASSOCIÉS[2024/10]
Examination procedure20.12.2022Loss of particular rights, legal effect: Claims
25.01.2023Despatch of communication of loss of particular rights: Claims {1}
15.03.2024Despatch of communication that the application is refused, reason: Examination on filing A.90(5) {1}
19.03.2024Application withdrawn by applicant  [2024/17]
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[I]  - WANG FEI ET AL., "Synthetic alpha-L-Threose nucleic acids targeting BcL-2 show gene silencing and in vivo antitumor activity for cancer therapy", APPLIED MATERIALS & INTERFACES, US, (20190926), vol. 11, no. 42, doi:10.1021/acsami.9b14324, ISSN 1944-8244, pages 38510 - 38518, XP093031784 [I] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1021/acsami.9b14324
 [I]  - Wang Fei ET AL., "Supporting Information", (20190926), URL: https://pubs.acs.org/doi/10.1021/acsami.9b14324#, (20230510), XP093045923 [I] 1-15 * the whole document *
 [I]  - LIU LING SUM ET AL., "alpha-L-Threose nucleic acids as biocompatible antisense oligonucleotides for suppressing gene expression in living cells", APPLIED MATERIALS & INTERFACES, US, (20180223), vol. 10, no. 11, doi:10.1021/acsami.8b01180, ISSN 1944-8244, pages 9736 - 9743, XP093031816 [I] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1021/acsami.8b01180
 [I]  - Ling Sum ET AL., "Supporting Information", (20180223), URL: https://pubs.acs.org/doi/10.1021/acsami.8b01180, (20230510), XP093045921 [I] 1-15 * the whole document *
 [A]  - ROBERTS THOMAS C. ET AL., "Advances in oligonucleotide drug delivery", NATURE REVIEWS DRUG DISCOVERY, NATURE PUBLISHING GROUP, GB, vol. 19, no. 10, doi:10.1038/S41573-020-0075-7, ISSN 1474-1776, (20200811), pages 673 - 694, (20200811), XP037256878 [A] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1038/s41573-020-0075-7
by applicantWO9839352
 WO9914226
 WO0047599
 WO0066604
 WO0123613
 WO2004046160
 WO2007031091
 WO2007090071
 WO2007134181
 WO2008049085
 WO2008150729
 WO2008154401
 WO2009006478
 WO2009067647
 WO2010036698
 WO2010077578
 WO2011017521
 WO2011156202
 WO2012078536
 WO2012109395
 WO2012118911
 WO2013022984
 WO2013154798
 WO2013179292
 WO2014076195
 WO2015113922
    - VESTER et al., Bioorg. Med. Chem. Lett., (20080000), vol. 18, pages 2296 - 2300
    - ECKSTEIN, Antisense and Nucleic Acid Drug Development, (20090000), vol. 10, pages 117 - 121
    - CROOKE et al., Nucleic Acids Research, (20200000), vol. 48, no. 10, pages 5235 - 5253
    - LIU et al., ACS Appl. Mater. Interfaces, (20180000), vol. 10, pages 9736 - 9743
    - HIRAO et al., Accounts of Chemical Research, (20120000), vol. 45, page 2055
    - FREIERALTMANN, Nucl. Acid Res., (19970000), vol. 25, pages 4429 - 4443
    - UHLMANN, Curr. Opinion in Drug Development, (20000000), vol. 3, no. 2, pages 293 - 213
    - DELEAVEYDAMHA, Chemistry and Biology, (20120000), vol. 19, page 937
    - MORITA et al., Bioorganic & Med. Chem. Lett., (20020000), vol. 12, pages 73 - 76
    - SETH et al., J. Org. Chem., (20100000), vol. 75, no. 5, pages 1569 - 81
    - MITSUOKA et al., Nucleic Acids Research, (20090000), vol. 37, no. 4, pages 1225 - 1238
    - WANSETH, J. Medical Chemistry, (20160000), vol. 59, pages 9645 - 9667
    - MERGNYLACROIX, Oligonucleotides, (20030000), vol. 13, pages 515 - 537
    - HANSEN et al., Chem. Comm., (19650000), vol. 36-38
    - SANTALUCIA, Proc Natl Acad Sci USA., vol. 95, pages 1460 - 1465
    - SUGIMOTO et al., Biochemistry, (19950000), vol. 34, pages 11211 - 11216
    - MCTIGUE et al., Biochemistry, (20040000), vol. 43, pages 5388 - 5405
    - MANGOS et al., J. AM. CHEM. SOC., (20030000), vol. 125, pages 654 - 661
    - FLUITER et al., Mol. Biosyst., (20090000), vol. 10, page 1039
    - RUKOV et al., Nucl. Acids Res. Vol., (20150000), vol. 43, pages 8476 - 8487
    - CARUTHERS et al., Methods in Enzymology, (19870000), vol. 154, pages 287 - 313
    - BASTIN, Organic Process Research & Development, (20000000), vol. 4, pages 427 - 435
    - ANSEL, Pharmaceutical Dosage Forms and Drug Delivery Systems, (19950000), pages 196,1456 - 1457
    - LANGER, Science, (19900000), vol. 249, pages 1527 - 1533
    - ZHANG et al., Chem. Inf. Model., (20120000), vol. 52, no. 10, pages 2796 - 2806
    - ZHANGCHAPUT, Current Protocols in Nucleic Acid Chemistry
 WO2009EP50349
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.